Clinical Trial Update: Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT) [Phase 2]

View source ↗

Summary

Phase 2 trial of BAY59-7939 (oral direct Factor Xa inhibitor) in acute symptomatic proximal deep vein thrombosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Venous Thrombosis

Drugs mentioned

• BAY59-7939

Snippet

Sponsor: Bayer | Conditions: Venous Thrombosis, Deep Vein Thrombosis | Phase 2 | Status: COMPLETED